



BETA DRUGS LIMITED

BETA DRUGS LIMITED THROUGH ITS SUBSIDIARY ADLEY LAB LTD RECEIVED DCGI NOD TO MANUFACTURE API OF ITS FIRST PARP INHIBITOR-RUCAPARIB.

Recently, Beta Drugs Ltd (BDL) through its subsidiary Adley lab ltd has received Drug Controller General of India (DCGI) approval to manufacture API of Rucaparib. BDL is among the very few Indian company that has developed this novel drug API i.e. PARP Inhibitor.

The company has received DCGI approval for 3 breakthrough products (Rucaparib, Cabozantinib & Azacitidine Oral) in the last 4 months. Approval of Rucaparib, a PARP inhibitor enables us to progress in the emerging era of personalized medicine.

Rucaparib is a targeted therapy for the treatment of Ovarian Cancer and Prostate Cancer. It significantly improves progression-free survival & has a tolerable safety profile.

Rucaparib is less than a year old molecule in Indian market and is expected to have a market size of 30-35 Cr in FY 22-23.

The company is continuously strengthening its position in both the formulations & API market and expects to launch many novel FTLs in the next 1-2 years. Rucaparib finished formulation approval from DCGI is expected in next 2 months.

The company ensures the Quality and affordability of its Oncology brands due to its ability to produce in-house API. Launch of Rucaparib is expected to give an edge to BDL over other oncology companies.



CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com